



3R MATRIX

	+	=	-
Right Sector (RS)	✓	■	■
Right Quality (RQ)	■	■	✓
Right Valuation (RV)	✓	■	■
	+ Positive	= Neutral	- Negative

What has changed in 3R MATRIX

	Old		New
RS	■	↔	■
RQ	■	↓	■
RV	■	↔	■

ESG Disclosure Score NEW

ESG RISK RATING 27.62
Updated Dec 08, 2022

Medium Risk

NEGL	LOW	MED	HIGH	SEVERE
0-10	10-20	20-30	30-40	40+

Source: Morningstar


Company details

Market cap:	Rs. 20,677 cr
52-week high/low:	Rs. 444 / 292
NSE volume: (No of shares)	25.3 lakh
BSE code:	500253
NSE code:	LICHSGFIN
Free float: (No of shares)	30.3 cr

Shareholding (%)

Promoters	45.2
FII	19.3
DII	22.7
Others	12.7

Price chart



Price performance

(%)	1m	3m	6m	12m
Absolute	-7.2	-1.8	-0.8	-3.3
Relative to Sensex	-5.5	-0.9	-4.1	-5.9

Sharekhan Research, Bloomberg

LIC Housing Finance Ltd
Weak Q3, Higher credit cost shores up PCR

NBFC	Sharekhan code: LICHSGFIN		
Reco/View: Buy	↔	CMP: Rs. 376	Price Target: Rs. 435
↑ Upgrade	↔ Maintain	↓ Downgrade	

Summary

- LICHF reported PAT at Rs. 480 crore (down 37% YoY/ up 58% q-o-q), which significantly lagged consensus and our estimates mainly led by higher credit costs. Credit cost stood at 115 bps annualized versus 87 bps q-o-q and 59 bps y-o-y. Company guided that there were no incremental write offs during the quarter however, higher credit cost is attributable towards shoring up the PCR to 51% versus 44% q-o-q.
- NIMs improved by 62 bps q-o-q and were stable y-o-y at 2.42%. However, there were no positive surprise in terms of margin uptick sequentially as improvement in NIMs was on expected lines due to certain one-off items that had compressed NIMs during the last quarter. We believe margins are expected to improve from hereon as a 115 bps rate hike taken in September and 35 bps rate hike taken in December will be fully reflected going forward which should lend support to the NIMs.
- Disbursements in individual home loan segment & non home loan segment declined by 11% y-o-y and 4% y-o-y respectively, while non-individual projects loan disbursements grew by 46% y-o-y. Total disbursements declined by 9% y-o-y/4% q-o-q. Overall loan book grew by 10% y-o-y/3% q-o-q. Individual home loan and non-home loan book grew by 14% y-o-y and 3% y-o-y respectively while developer book continued to decline by 23% y-o-y.
- Asset quality outlook remains stable. Gross Stage-2 assets declined by 8 bps q-o-q to 3.92%. GS3/NS3 asset ratio improved by 14 bps/36 bps q-o-q to 4.75%/2.40%, respectively. At the CMP, the stock trades at 0.8x/ 0.7x/ 0.6x its FY2023E/ FY2024E/ FY2025E BV estimates, respectively. We maintain our Buy rating with an unchanged PT of Rs. 435.

LIC Housing Finance (LICHF) reported weak performance in Q3FY2023. Net interest income grew by 10%y-o-y/38% q-o-q. NIMs improved by 62 bps q-o-q and were stable y-o-y at 2.42%. However, there was no positive surprise in terms of margin uptick sequentially as improvement in NIMs was on expected lines due to certain one-off items that dragged down NIMs during the last quarter. We believe margins are expected to improve from here on as 115 bps rate hike taken in September and 35 bps rate hike taken in December will be fully reflected going forward which should lend support to the NIMs. Total operating expenses grew by 39% y-o-y/ 10% q-o-q. Operating profits grew by 3% y-o-y/ 44% q-o-q. Total credit cost stood at 115 bps (as a % of loans) versus 87 bps q-o-q and 59 bps y-o-y. There were no incremental write offs during the quarter however, higher credit cost is attributable towards shoring up the PCR to 51% versus 44% q-o-q. PAT stood at Rs. 480 crore (down 37% y-o-y/up 58% q-o-q. Gross Stage-2 assets declined by 8 bps q-o-q to 3.92%. GS3/NS3 asset ratio improved by 14bps/36bps q-o-q to 4.75%/2.40%, respectively. The overall loan book grew by 10% y-o-y/3% q-o-q. Individual home loan and non-home loan book grew by 14% y-o-y and 3% y-o-y respectively while developer book continued to decline by 23% y-o-y. Disbursements in individual home loan segment & non home loan segment declined by 11% y-o-y and 4% y-o-y respectively, while non-individual projects loan disbursements grew by 46% y-o-y. Total disbursements declined by 9% y-o-y /4% q-o-q. Total restructured book at Rs. 1,420 crore (0.5% of loans versus 1.3% q-o-q).

Key positives

- PCR on GS-3 stood at ~51% versus. 44% q-o-q.
- Restructured book declined without any incremental write-offs.

Key negatives

- Business momentum was weak despite strong demand. Disbursements declined in individual segment.
- Opex growth was higher (39% y-o-y/ 10% q-o-q). Opex to Avg. loans stood at 43 bps vs 40 bps q-o-q and 34 bps y-o-y.

Management Commentary

- The company is confident of achieving ~12-13% disbursement growth in near term. Credit cost is expected to normalize at 45-50 bps going forward. Asset quality outlook is expected to remain stable to positive.
- Company guided that moderation is seen in housing demand due to a sharp increase in rates in short time. Prepayments were lower relatively during the quarter due to rate tightening scenario across the industry.

Our Call

Valuation – Maintain Buy rating on LIC Housing Finance with an unchanged PT of Rs. 435: At CMP, the stock trades at 0.8x/0.7x/ 0.6x its FY2023E/FY2024E/ FY2025E BV estimates. We believe valuations clearly factors in all the related concerns on margins, sub-par growth in business (losing market share), higher stress in the non-individual book and below par return ratios. We derive comfort from continued housing demand, which looks sustainable in near to medium term. Transmission of higher rates in home loans is happening faster that should eventually benefit LICHF. The company is optimistic in terms of improving asset-quality matrix, better margins and growth outlook, thereby improving return ratios. We believe valuations are inexpensive. Hence, we maintain our Buy rating on LICHF with an unchanged price target (PT) of Rs. 435.

Key Risks

Economic slowdown due to which slower loan growth and higher-than-anticipated credit cost.

Valuation (Standalone)

Particulars	FY22	FY23E	FY24E	FY25E
Net Interest Income	5,535	6,056	6,685	7,300
Net profit	2,287	2,431	3,204	3,500
EPS (Rs.)	41.6	44.2	58.2	64.0
P/E (x)	9.0	8.5	6.5	5.9
P/BV (x)	0.8	0.8	0.7	0.6
RoA (%)	0.9	0.9	1.0	1.0
RoE (%)	10.1	9.5	11.4	11.0

Source: Company; Sharekhan estimates

Key result highlights

- ◆ **Margins expected to improve gradually:** Net interest income grew by 10% y-o-y/38% q-o-q. NIMs improved by 62 bps q-o-q and were stable y-o-y at 2.42%. However, there were no positive surprise in terms of margin uptick sequentially as improvement in NIMs was on expected lines due to certain one-off items that had compressed NIMs during the last quarter. We believe margins are expected to improve from hereon as 115 bps rate hike taken in September and 35 bps rate hike taken in December will be fully reflected going forward which should lend support to the NIMs. Transmission of higher rates in home loans is happening faster that should eventually benefit LICHF. The company has raised rate around 210 bps versus RBI rate hike of 225 bps.
- ◆ **Moderate growth expectations:** Overall, the loan book grew by 10% y-o-y/3% q-o-q. Individual home loan and non-home loan book grew by 14% y-o-y and 3% y-o-y respectively while developer book continued to decline by 23% y-o-y. Around 83% of total loan book constitutes of individual home loans versus 80% last year. Disbursements in the individual home loan segment & non home loan segment declined by 11% y-o-y and 4% y-o-y respectively, while non-individual projects loan disbursements grew by 46% y-o-y. Total disbursements declined by 9% y-o-y /4% q-o-q. The company is confident of achieving ~12-13% disbursement growth in near term. However, some moderation is seen in demand due to a sharp increase in rates in short time. Prepayments were lower relatively during the quarter due to rate tightening scenario across the industry.
- ◆ **Credit cost guidance:** Total credit cost stood at 115 bps (as a % of loans) versus. 87 bps q-o-q and 59 bps y-o-y. There were no incremental write offs during the quarter however, higher credit cost is attributable towards shoring up the PCR to 51% versus 44% q-o-q. Credit cost is expected to normalise at 45-50 bps going forward. The company does not foresee further increase in PCR.
- ◆ **Asset quality outlook stable:** Gross Stage-2 assets declined by 8 bps q-o-q to 3.92%. GS3/NS3 asset ratio improved by 14 bps/36 bps q-o-q to 4.75%/2.40%, respectively. Total restructured book at Rs. 1,420 crore (0.5% of loans versus 1.3% q-o-q).

Results (Standalone)

Particulars	Rs cr				
	Q3FY23	Q3FY22	Y-o-Y %	Q2FY23	Q-o-Q %
Net Interest Income	1,606	1455	10%	1163	38%
Other income	37	70	-46%	43	-12%
Net Income	1643	1524	8%	1206	36%
Opex	288	207	39%	261	10%
Operating Profit	1,356	1317	3%	945	44%
Provisions	763	356	114%	566	35%
PAT	480	767	-37%	305	58%

Source: Company; Sharekhan Research

Outlook and Valuation

■ Sector View – Housing demand to grow exponentially

Long-term structural drivers remain strong for mortgages growth in India. There is an emerging trend across the young population to acquire homes at the early stages of life, which is likely to prop up demand. At present, higher interest rates are not affecting demand. Moreover, rising affordability and the government's schemes for affordable housing would support demand. Overall, asset-quality trends are stable.

■ Company Outlook – Sectoral tailwinds to lend support

We believe valuations clearly factor in all the related concerns - sub-par growth in business (losing market share), higher stress in the non-individual book, which in turn is leading to higher credit cost, lower margins, below par return ratio. Currently, housing demand is very strong, across tier-I , II, and III cities, which looks sustainable over the medium term. The company is optimistic in terms of improving asset-quality matrix, margin improvement, and growth outlook, thereby improving the return ratios. We believe margin should improve gradually as transmission of rate hikes happens and credit cost is expected to normalise going forward due to accelerated write offs in past & as PCR now stands at ~51%.

■ Valuation – Maintain Buy rating on LIC Housing Finance with an unchanged PT of Rs. 435

At CMP, the stock trades at 0.8x/0.7x/ 0.6x its FY2023E/FY2024E/ FY2025E BV estimates. We believe valuations clearly factors in all the related concerns on margins, sub-par growth in business (losing market share), higher stress in the non-individual book and below par return ratios. We derive comfort from continued housing demand, which looks sustainable in near to medium term. Transmission of higher rates in home loans is happening faster that should eventually benefit LICHF. The company is optimistic in terms of improving asset-quality matrix, better margins and growth outlook, thereby improving return ratios. We believe valuations are inexpensive. Hence, we maintain our Buy rating on LICHF with an unchanged price target (PT) of Rs. 435.

Peer Comparison

Particulars	CMP	MCAP (Rs Cr)	P/E (x)		P/B (x)		RoE (%)		RoA (%)	
	Rs/Share		FY23E	FY24E	FY23E	FY24E	FY23E	FY24E	FY23E	FY24E
LIC Housing	376	20,677	8.5	6.5	0.8	0.7	9.5	11.4	0.9	1.0
Can Fin Homes	580	7,720	12.7	11.5	2.1	1.8	18.0	16.8	2.0	1.8

Source: Company, Sharekhan research

About company

LICHF is one of the second largest HFCs in India having one of the widest networks across the country. LICHF is promoted by Life Insurance Corporation in which it currently holds 45.24% shares in HFC. Over the years, they have grown stronger and built a huge base of around 30 lakh homeowners. It has an extensive reach to address the home loan needs of prospective borrowers with a well-trained and well-spread network of 282 marketing offices and around 10,000 marketing intermediaries.

Investment theme

LICHF has seen steady growth in the past, however performance of the high-yielding developer loan book portion such as LAP/Developer loans continues to be below par. We believe valuations clearly factor in all the related concerns - sub-par growth in business (losing market share), higher stress in the non-individual book, which in turn is leading to higher credit cost, lower margins, below par return ratio. We derive comfort from continued housing demand which looks sustainable in near to medium term. Transmission of higher rates in home loans is happening faster that should eventually benefit LICHF. Overall asset quality outlook is expected to remain stable.

Key Risks

Economic slowdown due to which slower loan growth and higher-than-anticipated credit cost

Additional Data

Key management personnel

Mr. Y. Viswanatha Gowd	MD & CEO
Mr. Sudipto Sil	CFO
Mr. Ashwani Ghai	COO

Source: Company Website

Top 10 shareholders

Sr. No.	Holder Name	Holding (%)
1	LIFE INSURANCE CORP OF INDIA	45.24
2	ICICI PRUDENTIAL ASSET MANAGEMENT CO LTD	5.56
3	NIPPON LIFE INDIA ASSET MANAGEMENT LTD	2.74
4	SBI FUNDS MANAGEMENT LTD	2.55
5	GOVERNMENT PENSION FUND GLOBAL	2.53
6	BANK MUSCAT INDIA FUND	2.09
7	NORGES BANK	2.08
8	VANGUARD GROUP INC.	1.98
9	HDFC LIFE INSURANCE CO INC	1.47
10	PRUDENTIAL PLC	1.40

Source: Bloomberg

Sharekhan Limited, its analyst or dependant(s) of the analyst might be holding or having a position in the companies mentioned in the article.

Understanding the Sharekhan 3R Matrix

Right Sector	
Positive	Strong industry fundamentals (favorable demand-supply scenario, consistent industry growth), increasing investments, higher entry barrier, and favorable government policies
Neutral	Stagnancy in the industry growth due to macro factors and lower incremental investments by Government/private companies
Negative	Unable to recover from low in the stable economic environment, adverse government policies affecting the business fundamentals and global challenges (currency headwinds and unfavorable policies implemented by global industrial institutions) and any significant increase in commodity prices affecting profitability.
Right Quality	
Positive	Sector leader, Strong management bandwidth, Strong financial track-record, Healthy Balance sheet/cash flows, differentiated product/service portfolio and Good corporate governance.
Neutral	Macro slowdown affecting near term growth profile, Untoward events such as natural calamities resulting in near term uncertainty, Company specific events such as factory shutdown, lack of positive triggers/events in near term, raw material price movement turning unfavourable
Negative	Weakening growth trend led by led by external/internal factors, reshuffling of key management personal, questionable corporate governance, high commodity prices/weak realisation environment resulting in margin pressure and deteriorating balance sheet
Right Valuation	
Positive	Strong earnings growth expectation and improving return ratios but valuations are trading at discount to industry leaders/historical average multiples, Expansion in valuation multiple due to expected outperformance amongst its peers and Industry up-cycle with conducive business environment.
Neutral	Trading at par to historical valuations and having limited scope of expansion in valuation multiples.
Negative	Trading at premium valuations but earnings outlook are weak; Emergence of roadblocks such as corporate governance issue, adverse government policies and bleak global macro environment etc warranting for lower than historical valuation multiple.

Source: Sharekhan Research

Sharekhan

by BNP PARIBAS

Know more about our products and services

For Private Circulation only

Disclaimer: This document has been prepared by Sharekhan Ltd. (SHAREKHAN) and is intended for use only by the person or entity to which it is addressed to. This Document may contain confidential and/or privileged material and is not for any type of circulation and any review, retransmission, or any other use is strictly prohibited. This Document is subject to changes without prior notice. This document does not constitute an offer to sell or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Though disseminated to all customers who are due to receive the same, not all customers may receive this report at the same time. SHAREKHAN will not treat recipients as customers by virtue of their receiving this report.

The information contained herein is obtained from publicly available data or other sources believed to be reliable and SHAREKHAN has not independently verified the accuracy and completeness of the said data and hence it should not be relied upon as such. While we would endeavour to update the information herein on reasonable basis, SHAREKHAN, its subsidiaries and associated companies, their directors and employees ("SHAREKHAN and affiliates") are under no obligation to update or keep the information current. Also, there may be regulatory, compliance, or other reasons that may prevent SHAREKHAN and affiliates from doing so. This document is prepared for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. Recipients of this report should also be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The user assumes the entire risk of any use made of this information. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved) and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. We do not undertake to advise you as to any change of our views. Affiliates of Sharekhan may have issued other reports that are inconsistent with and reach different conclusions from the information presented in this report.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SHAREKHAN and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

The analyst certifies that the analyst has not dealt or traded directly or indirectly in securities of the company and that all of the views expressed in this document accurately reflect his or her personal views about the subject company or companies and its or their securities and do not necessarily reflect those of SHAREKHAN. The analyst and SHAREKHAN further certifies that neither he or his relatives or Sharekhan associates has any direct or indirect financial interest nor have actual or beneficial ownership of 1% or more in the securities of the company at the end of the month immediately preceding the date of publication of the research report nor have any material conflict of interest nor has served as officer, director or employee or engaged in market making activity of the company. Further, the analyst has also not been a part of the team which has managed or co-managed the public offerings of the company and no part of the analyst's compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this document. Sharekhan Limited or its associates or analysts have not received any compensation for investment banking, merchant banking, brokerage services or any compensation or other benefits from the subject company or from third party in the past twelve months in connection with the research report.

Either, SHAREKHAN or its affiliates or its directors or employees / representatives / clients or their relatives may have position(s), make market, act as principal or engage in transactions of purchase or sell of securities, from time to time or may be materially interested in any of the securities or related securities referred to in this report and they may have used the information set forth herein before publication. SHAREKHAN may from time to time solicit from, or perform investment banking, or other services for, any company mentioned herein. Without limiting any of the foregoing, in no event shall SHAREKHAN, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind.

Compliance Officer: Ms. Binkle Oza; Tel: 022-61150000; email id: complianceofficer@sharekhan.com;

For any queries or grievances kindly email igc@sharekhan.com or contact: myaccount@sharekhan.com.

Registered Office: Sharekhan Limited, The Ruby, 18th Floor, 29 Senapati Bapat Marg, Dadar (West), Mumbai – 400 028, Maharashtra, INDIA, Tel: 022 - 67502000/ Fax: 022 - 24327343. Sharekhan Ltd.: SEBI Regn. Nos.: BSE / NSE / MSEI (CASH / F&O/ CD) / MCX - Commodity: INZ000171337; DP: NSDL/CDSL-IN-DP-365-2018; PMS: INP000005786; Mutual Fund: ARN 20669; Research Analyst: INH000006183.

Disclaimer: Client should read the Risk Disclosure Document issued by SEBI & relevant exchanges and the T&C on www.sharekhan.com; Investment in securities market are subject to market risks, read all the related documents carefully before investing.